PDF (2577K)
摘要
目的 探讨放疗联合酪氨酸激酶抑制剂(TKI)治疗对表皮生长因子受体(EGFR)突变型的局部晚期非小细胞肺癌(LA-NSCLC)患者生存及不良反应的影响。方法 收集 2012 年 1 月至 2024 年 3 月于大连医科大学附属第二医院治疗的 EGFR 突变型 LA-NSCLC 患者 45 例,在全身化疗基础上,根据最初治疗方式分为 TKI 联合放疗组(TKI+RT 组)16 例和 TKI 治疗组(TKI 组)29 例。比较两组患者无进展生存(PFS)、总生存(OS)、无局部区域复发生存(LRRFS)、无远处转移生存(DMFS)及治疗期间的不良反应,并对影响两组患者生存结果的因素进行分析,同时进行相关生存率以及亚组分析。结果 全组患者经过 43.8(32.4,59.8)个月的中位随访,TKI+RT 组和 TKI 组患者中位 PFS 为 24.2 个月 vs 14.2 个月(P=0.006);中位 OS 为 55.3 个月 vs 43.4 个月(P=0.415);中位 LRRFS 为 38.5 个月 vs 15.4 个月(P<0.001);中位 DMFS 为 26.9 个月 vs 15.8 个月(P=0.020)。其中,2 年 PFS 率为 53.3% vs 16.1%(P=0.018);2 年 LRRFS 率为 64.6% vs 16.7%(P=0.003);2 年 DMFS 率为 60.0% vs 26.6%(P=0.041)。进一步分析显示,TKI+RT 治疗方案在不同特征人群中均显示出 PFS、LRRFS、DMFS 获益。EGFR 19del 是患者 PFS 的独立保护因素(HR=0.47,P=0.036),TKI+RT 治疗则是影响患者 LRRFS 的独立保护因素(HR=0.31,P=0.005)。整个治疗期间所有患者耐受性良好,均未见严重不良事件发生。结论 针对 EGFR 突变阳性的 LA-NSCLC 患者,放疗联合 TKI 治疗可显著提高 PFS、LRRFS、DMFS,且不会额外增加不良反应的发生,但 OS 的提高不明显,仍需今后研究进一步证实。
Abstract
Objective To investigate the effect of radiotherapy combined with tyrosine kinase inhibitor (TKI) on survival and toxicities in patients with locally advanced, EGFR-mutant non-small cell lung cancer (LA-NSCLC). Methods A total of 45 patients with EGFR-mutant locally advanced non-small cell lung cancer who were treated in the Second Affiliated Hospital of Dalian Medical University from January 2012 to March 2024 were collected. On the basis of systemic chemotherapy, according to the initial treatment modality, patients were divided into the TKI combined with radiotherapy group (TKI+RT group, n=16) and the TKI group (n=29). Progression-free survival (PFS), overall survival (OS), locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), and treatment-related toxicities were compared between the two groups. Factors affecting survival outcomes in the two groups were analyzed. Finally, survival rates and subgroup analyses were also performed. Results After a median follow-up of 43.8 (32.4, 59.8) months in the overall cohort, the median PFS was 24.2 months in patients receiving TKI+RT versus 14.2 months in those receiving TKI (P=0.006). The median OS was 55.3 months versus 43.4 months (P=0.415), the median LRRFS was 38.5 months versus 15.4 months (P<0.001), and the median DMFS was 26.9 months versus 15.8 months (P=0.020), respectively. The 2-year PFS rates were 53.3% versus 16.1% (P=0.018), the 2-year LRRFS rates were 64.6% versus 16.7% (P=0.003), and the 2-year DMFS rates were 60.0% versus 26.6% (P=0.041). Subgroup analysis showed that the TKI+RT treatment regimen demonstrated benefits in PFS, LRRFS, and DMFS across populations with different clinical characteristics. EGFR 19del was an independent protective factor for PFS (HR=0.47, P=0.036), while TKI+RT treatment was an independent protective factor affecting LRRFS (HR=0.31, P=0.005). Patients tolerated treatment well throughout the treatment period, and no severe adverse events were observed. Conclusion For patients with EGFR-mutant LA-NSCLC, radiotherapy combined with TKI treatment significantly improved PFS, LRRFS, and DMFS without additionally increasing the incidence of adverse reactions. However, the improvement in OS was not significant, and further studies are needed for confirmation.
关键词
Key words
[Author(id=1329765371125310405, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=15642929777@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329765371192419274, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, authorId=1329765371125310405, language=EN, stringName=Yuanxin XU, firstName=Yuanxin, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1 Department of Radiation Oncology , the Second Hospital of Dalian Medical University, Dalian 116027, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329765371246945230, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, authorId=1329765371125310405, language=CN, stringName=徐源欣, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1 大连医科大学附属第二医院 肿瘤放疗科 , 辽宁 大连 116027, bio={"content":"徐源欣(1999-),女,医师。E-mail: 15642929777@163.com
"}, bioImg=null, bioContent=徐源欣(1999-),女,医师。E-mail: 15642929777@163.com
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329765370957538237, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, xref=1, ext=[AuthorCompanyExt(id=1329765370974315454, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, companyId=1329765370957538237, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1 Department of Radiation Oncology , the Second Hospital of Dalian Medical University, Dalian 116027, China), AuthorCompanyExt(id=1329765370991092671, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, companyId=1329765370957538237, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1 大连医科大学附属第二医院 肿瘤放疗科 , 辽宁 大连 116027)])]), Author(id=1329765371297276881, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329765371364385748, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, authorId=1329765371297276881, language=EN, stringName=Yingying TIAN, firstName=Yingying, middleName=null, lastName=TIAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2 Department of Radiation Therapy 2, Qingdao Central Hospital, University of Health and Rehabilitation Sciences , Qingdao 266042, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329765371414717399, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, authorId=1329765371297276881, language=CN, stringName=田莹莹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2 康复大学青岛中心医院 放射治疗二科 ,山东 青岛 266042, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329765371041424320, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, xref=2, ext=[AuthorCompanyExt(id=1329765371058201537, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, companyId=1329765371041424320, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2 Department of Radiation Therapy 2, Qingdao Central Hospital, University of Health and Rehabilitation Sciences , Qingdao 266042, China), AuthorCompanyExt(id=1329765371074978754, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, companyId=1329765371041424320, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2 康复大学青岛中心医院 放射治疗二科 ,山东 青岛 266042)])]), Author(id=1329765371469243353, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=799832582@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329765371532157917, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, authorId=1329765371469243353, language=EN, stringName=Zhuo ZHANG, firstName=Zhuo, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1 Department of Radiation Oncology , the Second Hospital of Dalian Medical University, Dalian 116027, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329765371582489568, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, authorId=1329765371469243353, language=CN, stringName=张卓, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1 大连医科大学附属第二医院 肿瘤放疗科 , 辽宁 大连 116027, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329765370957538237, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, xref=1, ext=[AuthorCompanyExt(id=1329765370974315454, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, companyId=1329765370957538237, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1 Department of Radiation Oncology , the Second Hospital of Dalian Medical University, Dalian 116027, China), AuthorCompanyExt(id=1329765370991092671, tenantId=1045748351789510663, journalId=1155139928303341746, articleId=1329765369481143222, companyId=1329765370957538237, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1 大连医科大学附属第二医院 肿瘤放疗科 , 辽宁 大连 116027)])])]
徐源欣,田莹莹,张卓.
EGFR突变型局部晚期非小细胞肺癌放疗联合EGFR-TKI的治疗研究[J].
大连医科大学学报, 2026, 48(3): 231-239 DOI:10.11724/jdmu.2026.03.06
| [1] |
Filho AM, Laversanne M, Ferlay J, et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide[J]. Int J Cancer, 2025, 156(7): 1336-1346. DOI: 10.1002/ijc.35278.
|
| [2] |
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA A Cancer J Clin, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820.
|
| [3] |
Wu YJ, He SY, Cao MD, et al. Comparative analysis of cancer statistics in China and the United States in 2024[J]. Chin Med J, 2024, 137(24): 3093-3100. DOI: 10.1097/cm9.0000000000003442.
|
| [4] |
Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment[J]. Mayo Clin Proc, 2019, 94(8): 1623-1640. DOI: 10.1016/j.mayocp.2019.01.013.
|
| [5] |
Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. J Clin Oncol, 2022, 40(12): 1301-1311. DOI: 10.1200/jco.21.01308.
|
| [6] |
Aredo JV, Mambetsariev I, Hellyer JA, et al. Durvalumab for stage Ⅲ EGFR-mutated NSCLC after definitive chemoradiotherapy[J]. J Thorac Oncol, 2021, 16(6): 1030-1041. DOI: 10.1016/j.jtho.2021.01.1628.
|
| [7] |
Wang XH, Meng X, Cai GX, et al. Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma[J]. Int Immunopharmacol, 2024, 129: 111684. DOI: 10.1016/j.intimp.2024.111684.
|
| [8] |
Yagishita S, Horinouchi H, Katsui Taniyama T, et al. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage Ⅲ nonsquamous non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2015, 91(1): 140-148. DOI: 10.1016/j.ijrobp.2014.08.344.
|
| [9] |
Akamatsu H, Kaira K, Murakami H, et al. The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy[J]. Am J Clin Oncol, 2014, 37(2): 144-147. DOI: 10.1097/coc.0b013e31826e04f9.
|
| [10] |
Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma[J]. Lab Investig, 2014, 94(2): 129-137. DOI: 10.1038/labinvest.2013.147.
|
| [11] |
Xing LG, Wu G, Wang LH, et al. Erlotinib versus etoposide/cisplatin with radiation therapy in unresectable stage Ⅲ epidermal growth factor receptor mutation-positive non-small cell lung cancer: a multicenter, randomized, open-label, phase 2 trial[J]. Int J Radiat Oncol, 2021, 109(5): 1349-1358. DOI: 10.1016/j.ijrobp.2020.11.026.
|
| [12] |
Nassar AH, Kim SY, Aredo JV, et al. Consolidation osimertinib versus durvalumab versus observation after concurrent chemoradiation in unresectable EGFR-mutant NSCLC: a multicenter retrospective cohort study[J]. J Thorac Oncol, 2024, 19(6): 928-940. DOI: 10.1016/j.jtho.2024.01.012.
|
| [13] |
Bi N, Xu KP, Ge H, et al. Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: a multi-center cohort study[J]. J Natl Cancer Cent, 2023, 3(1): 65-71. DOI: 10.1016/j.jncc.2022.11.003.
|
| [14] |
Lu S, Ahn MJ, Reungwetwattana T, et al. Osimertinib after definitive chemoradiotherapy in unresectable stage Ⅲ epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase Ⅲ LAURA study[J]. Ann Oncol, 2024, 35(12): 1116-1125. DOI: 10.1016/j.annonc.2024.08.2243.
|
| [15] |
Yu J, Meng X, Ge H, et al. PL04.13 aumolertinib maintenance after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer: interim results of the phase Ⅲ study (POLESTAR)[J]. J Thorac Oncol, 2024, 19(10): S6-S7. DOI: 10.1016/j.jtho.2024.09.021.
|